ArticleNews reportPHN-05012026-10-31 15:09 CT

FDA advisers narrowly vote to add 6 peptides to a drug compounding list. What's next? - ABC News

Source · Breaking News, Latest News and Videos

TLDR

ABC News reports that FDA advisers narrowly recommended adding six peptides to a drug compounding list, despite unanimous opposition from FDA staff scientists. The recommendation is non-binding and requires FDA review and rulemaking; inclusion would not establish that the peptides are safe or effective.

01—Key points

01Advisers supported BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, but rejected emideltide over weak evidence.
02FDA scientists cited inadequate clinical data, inconsistent formulations and potential harmful immune reactions; supporters argued regulated compounding could reduce harm.
03The article says FDA review, proposed rules and public feedback could take up to a year.

Why it matters Editorial

The recommendations could change peptide compounding rules while raising concerns that patients may mistake list inclusion for FDA approval of safety and effectiveness.

Read the original at Breaking News, Latest News and Videos↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.